Novel mutant-selective EGFR kinase inhibitors against EGFR T790M-Reference-Cited by-同舟云学术

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

Published:2009-12 Issue:7276 Volume:462 Page:1070-1074
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Zhou Wenjun,Ercan Dalia,Chen Liang,Yun Cai-Hong,Li Danan,Capelletti Marzia,Cortot Alexis B.,Chirieac Lucian,Iacob Roxana E.,Padera Robert,Engen John R.,Wong Kwok-Kin,Eck Michael J.,Gray Nathanael S.,Jänne Pasi A.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/nature08622.pdf

Reference28 articles.

1. Mok, T. S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947–957 (2009)

2. Pao, W. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, 1–11 (2005)

3. Kobayashi, S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786–792 (2005)

4. Li, D. et al. Bronchial and peripheral murine lung carcinomas induced by T790M–L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 12, 81–93 (2007)

5. Besse, B. et al. Neratinib (HKI-272), an irreversible pan-ErbB receptor tyrosine kinase inhibitor: preliminary results of a phase 2 trial in patients with advanced non-small cell lung cancer. Eur. J. Cancer Suppl. 6, 64, abstr. 203 (2008)

Cited by 879 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FDA-approved small molecule kinase inhibitors for cancer treatment (2001–2015): Medical indication, structural optimization, and binding mode Part I;Bioorganic & Medicinal Chemistry;2024-09

2. Discovery of new cyclopropane sulfonamide derivatives as EGFR inhibitors to overcome C797S-mediated resistance and EGFR double mutation;European Journal of Medicinal Chemistry;2024-09

3. Design, preparation and biological evaluation of new Rociletinib-inspired analogs as irreversible EGFR inhibitors to treat non-small-cell-lung cancer;Bioorganic & Medicinal Chemistry;2024-09

4. Targeting EGFR with molecular degraders as a promising strategy to overcome resistance to EGFR inhibitors;Future Medicinal Chemistry;2024-08-29

5. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24